HAIER BIOMEDICAL(688139) 搜狐财经·2025-03-31 11:58Core Viewpoint - Haier Biomedical's stock closed at 34.58 yuan, down 2.40%, with a rolling PE ratio of 29.99 times and a total market capitalization of 10.995 billion yuan [1] Group 1: Company Overview - Haier Biomedical focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users, through two main segments: life sciences and medical innovation [2] - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health [2] - Key products include low-temperature storage boxes, automated biological sample storage, and various automated medication products [2] Group 2: Financial Performance - In the latest annual report for 2024, the company achieved operating revenue of 2.284 billion yuan, a year-on-year increase of 0.13%, and a net profit of 367 million yuan, a year-on-year decrease of 9.71% [3] - The sales gross margin stood at 47.99% [3] Group 3: Market Position - The average PE ratio for the medical device industry is 44.72 times, with a median of 32.59 times, placing Haier Biomedical at the 69th position in the industry [1][3] - As of February 28, 2025, the number of shareholders increased to 13,246, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1]